General Information of Drug Combination (ID: DC96CTX)

Drug Combination Name
Larotrectinib Rotenone
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs Larotrectinib   DM26CQR Rotenone   DMV04ES
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 24.21
Bliss Independence Score: 23.29
Loewe Additivity Score: 0.258
LHighest Single Agent (HSA) Score: 3.867

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Larotrectinib
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [2]
Larotrectinib Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [4]
NT-3 growth factor receptor (TrkC) TTXABCW NTRK3_HUMAN Inhibitor [4]
BDNF/NT-3 growth factors receptor (TrkB) TTKN7QR NTRK2_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Rotenone
Disease Entry ICD 11 Status REF
Piscicide N.A. Approved [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.